Immunocore (NASDAQ:IMCR) Receives “Buy” Rating from HC Wainwright

Immunocore (NASDAQ:IMCR)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $100.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 244.46% from the stock’s previous close.

Other analysts have also issued research reports about the stock. Morgan Stanley reaffirmed an “equal weight” rating and set a $35.00 target price (down previously from $74.00) on shares of Immunocore in a report on Friday, December 13th. Mizuho lowered shares of Immunocore from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $72.00 to $38.00 in a report on Monday, November 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $71.00 target price on shares of Immunocore in a report on Thursday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Immunocore currently has a consensus rating of “Moderate Buy” and an average target price of $65.64.

Immunocore Stock Performance

IMCR stock opened at $29.03 on Friday. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The company has a 50 day moving average price of $30.06 and a 200 day moving average price of $31.95. Immunocore has a fifty-two week low of $27.69 and a fifty-two week high of $72.05. The stock has a market capitalization of $1.45 billion, a PE ratio of -30.56 and a beta of 0.77.

Institutional Investors Weigh In On Immunocore

Several institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its position in Immunocore by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 35,492 shares of the company’s stock valued at $1,047,000 after acquiring an additional 420 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Immunocore in the 4th quarter valued at $25,000. China Universal Asset Management Co. Ltd. lifted its position in Immunocore by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock valued at $248,000 after acquiring an additional 960 shares in the last quarter. NEOS Investment Management LLC lifted its position in Immunocore by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock worth $330,000 after buying an additional 1,102 shares in the last quarter. Finally, Pier Capital LLC lifted its position in Immunocore by 1.4% during the 3rd quarter. Pier Capital LLC now owns 82,480 shares of the company’s stock worth $2,568,000 after buying an additional 1,174 shares in the last quarter. 84.50% of the stock is owned by institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.